Overview

A Phase 1 Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Repotrectinib in Advanced Cancer Patients

Status:
Recruiting

Trial end date:
2025-12-01

Target enrollment:

Participant gender:

Summary

This is a Phase 1 study to evaluate the effect of moderate or severe hepatic impairment on the PK of repotrectinib in patients with advanced cancer.

Phase:

Phase 1

Details

Lead Sponsor:

Turning Point Therapeutics, Inc.